Welcome to our dedicated page for Lilly Eli & news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & stock.
Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Innovent Biologics and Eli Lilly expand their strategic partnership to enhance cancer treatment options in China. Innovent will acquire sole commercialization rights for Cyramza® and Retsevmo® upon approval, and a right of first negotiation for Pirtobrutinib. Cyramza® is crucial for gastric and liver cancer, filling a significant treatment gap in China. The deal involves a total payment of US$45 million upon regulatory approvals. This agreement aims to increase Innovent's oncology portfolio to seven products, benefiting cancer patients.
On March 26, 2022, Eli Lilly released data from pivotal Phase 3 studies on OLUMIANT (baricitinib) for adults with severe alopecia areata, showing nearly 40% of patients on 4-mg achieved at least 80% scalp coverage at 52 weeks. Results indicate significant eyelash and eyebrow regrowth in those treated. The FDA granted priority review for OLUMIANT in February 2022, marking it as a potential first-in-disease treatment. Safety profiles were consistent over 52 weeks, with no new safety signals reported, reinforcing its promise as a key therapeutic option.
Eli Lilly and Company (NYSE: LLY) announced significant results from its ADvocate program, revealing that over 50% of patients with moderate-to-severe atopic dermatitis treated with the investigational drug lebrikizumab experienced a 75% reduction in disease severity (EASI-75) after 16 weeks. The treatment also provided substantial improvements in itch and skin clearance. Safety evaluations indicated a lower frequency of adverse events compared to placebo. Lilly plans to submit regulatory filings for lebrikizumab by the end of 2022.
Eli Lilly and Company (NYSE: LLY) received a complete response letter (CRL) from the FDA for its Biologics License Application (BLA) for sintilimab injection, a PD-1 inhibitor for treating nonsquamous non-small cell lung cancer (NSCLC). The FDA's letter indicates the application cannot be approved in its current form, recommending an additional clinical trial comparing sintilimab to standard care. Sintilimab is already approved in China for various cancer indications and is undergoing multiple clinical studies. Lilly is now evaluating next steps for the sintilimab program in the U.S.
The EMPA-KIDNEY trial, assessing Jardiance (empagliflozin) for chronic kidney disease (CKD), is set to stop early due to positive efficacy results from the Independent Data Monitoring Committee. This trial, the largest of its kind in CKD, involves over 6,600 participants with various kidney function levels. The primary goal is to evaluate kidney disease progression and cardiovascular death. The trial's findings aim to address significant unmet medical needs in CKD, a global health crisis affecting millions. Detailed results will be presented later this year.
Eli Lilly and Company (NYSE: LLY) will present data on pirtobrutinib and Verzenio at the 2022 American Association for Cancer Research (AACR) Annual Meeting from April 8-13, 2022. Key presentations include the BRUIN Phase 1b study results on pirtobrutinib for chronic lymphocytic leukemia and data on Verzenio’s efficacy against CDK4/6i resistance in breast cancer. These findings will enhance understanding of treatment options and potential outcomes for patients with relapsed conditions. Posters will be accessible on-demand until July 13, 2022.
Eli Lilly and Company (NYSE: LLY) is set to participate in the Barclays Global Healthcare Conference on March 15, 2022. Patrik Jonsson, senior vice president and president of Lilly Immunology, will engage in a fireside chat at 10:15 a.m. ET. Investors and the public can access a live audio webcast through Lilly's Investor website. A replay will be available for approximately 90 days. Lilly continues its commitment as a global healthcare leader, dedicated to discovering life-changing medicines.
Eli Lilly and Boehringer Ingelheim announced that Jardiance (empagliflozin) demonstrated a 36% higher clinical benefit in adults hospitalized for acute heart failure in the EMPULSE phase III trial, compared to placebo. The study, comprising 530 patients, evaluated composite endpoints including mortality and frequency of heart failure events. Jardiance also improved quality of life as measured by the Kansas City Cardiomyopathy Questionnaire. The FDA has previously approved Jardiance for reducing cardiovascular death risk in heart failure patients, contributing to its third approval related to the EMPOWER program.
Eli Lilly and Company (NYSE: LLY) will participate in the Cowen Health Care Conference on March 8, 2022. Anat Ashkenazi, Lilly's CFO, will engage in a virtual fireside chat at 10:30 a.m. Eastern Time. A live audio webcast will be accessible on Lilly's Investor website, with a replay available for 90 days. Lilly is dedicated to creating high-quality medicines and enhancing community well-being through philanthropy. For more details, visit www.lilly.com.
The FDA has approved Jardiance (empagliflozin) 10 mg for reducing the risk of cardiovascular death and hospitalization for heart failure in adults. This marks a significant advancement for nearly 3 million U.S. adults with heart failure with preserved ejection fraction, expanding treatment options in a sector with limited alternatives. Jardiance previously received approval for heart failure with reduced left ventricular ejection fraction. The approval is based on the EMPEROR-Preserved phase III trial, which showed a 21% risk reduction in cardiovascular events.